PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) is undervalued ahead of potential shareholder cash returns, according to Panmure Liberum, which initiated coverage with a 'buy' rating and a 200 pence target.
In its 6 October note, the broker argued that cash and the listed Seaport Therapeutics stake alone exceeded PureTech's market value, leaving other assets effectively unrecognised.
Supporting the cash return case, Panmure Liberum estimated that June 2026 cash of $220 million would fund operations until at least the end of 2028.
That runway includes $70 million earmarked for Celea Therapeutics and does not depend on further investment exits, potentially leaving disposal proceeds available for shareholders.
The broker identified a gradual sale of part of the Seaport holding as the most likely near-term opportunity to release cash, consistent with management's distribution strategy.
However, it cautioned that the timing and scale of cash inflows remain uncertain.
The prospect of distributions also reflects a 2025 strategic review that shifted PureTech towards earlier external investment, reversing an approach that increased cash burn and concentrated risk.
Under that model, PureTech shares drug development costs with co-investors while retaining equity stakes, royalties and milestone payments.
The broker said removing Seaport and Celea from consolidated accounts had reduced operating expenses, while expected Gallop Oncology funding should further lower the parent company's costs.
That reliance on external investors also carries risk, with continued development dependent on securing third-party funding, the analysts warned.
The next milestones are Seaport's phase IIb depression trial results and Gallop's Series A financing, both expected in the first half of 2027.
